UK: M&A In Life Sciences Set For Revival In 2017

Last Updated: 20 March 2017
Article by Matthew Thaxter

This week our colleague Sriram Prakash, Deloitte's global lead for mergers and acquisitions (M&A) insight, published the cross industry M&A Index Outlook for 2017.1 This week's blog draws on the report to explore the outlook for, and key drivers of, M&A in the Life Sciences industry in 2017.

The headline figures and trends from the M&A Index 2017 report include a specific reference to the Life Sciences and Healthcare (LSHC) industry. The insights identified include the following:

  • in 2016, the LSHC sector announced around $215 billion worth of deals - about half the level of the previous two years
  • the value of deals in the pharmaceutical industry in 2016 totalled $75 billion - down from $200 billion in 2015
  • while LSHC volumes remained strong, values declined sharply, driven by the fall in mega-deals
  • only three so called 'mega deals' were announced in 2016, compared to eight in 2015
  • $168 billion worth of announced deals were withdrawn in 2016 compared to $97 billion in 2015
  • the average price to earnings multiple on the 2016 deals still remained relatively high, at 32.6 compared to 35.8 in 2015
  • the US was the most active market and contributed to nearly 60 per cent of the announced deals
  • Europe was the only region that saw an uptick in deals, with France being the most active target country
  • cross-border deals in 2016 stood at $60 billion - down from $154 billion in 2015.

While 2016 failed to reach the levels of deal-making we have become accustomed to, a key contributory factor was the heightened political and economic uncertainty experienced throughout the past year. However, as we look ahead to 2017, there are a number of drivers that point to a year of increased M&A activity within the Life Sciences sector which I explore below.

Last year's political uncertainty, particularly surrounding Brexit and the US presidential elections certainly dampened the appetite for deals, with the associated uncertainty from the pricing and tax environments among the primary drivers of stalled activity. However, Deloitte now expects the new environment in the US to be more favourable for M&A than before. The new US administration is expected to relax corporate tax rates and US-based pharmaceutical companies are now likely to see this as an opportunity to replenish their pipelines with acquisitions of promising smaller peers, rather than re-invest in internal R&D.

The Centre's recent report, Measuring the return from pharmaceutical innovation 2016 further supports the notion that pharmaceutical companies are increasingly likely to pursue external innovation, rather than invest in internal asset development.2 Our analysis found that a growing proportion of the 12 original cohort companies' late-stage pipeline value has become internally-generated (57 per cent in 2016 compared to 39 percent in 2013), but that this correlates with a continued decline in forecast late-stage pipeline value ($833 billion in 2016 compared to $913 billion in 2013). Hence, we predicted in our report that an increase in M&A activity is on the horizon as companies attempt to boost the forecast value of their late-stage pipelines through the purchase of externally-innovated assets.

The Centre's research also found that unprecedented pressure from industry payers has increased the importance of value demonstration, and this will spur collaborations, including M&A, as companies look to better protect against the cost of attrition and provide some risk sharing. Consolidation, particularly within specialist areas will be prevalent, where unmet medical needs create the scope to command high margins. Related to this, the theme of de-diversification is emerging as companies are increasingly focussing on priority areas and exiting non-core areas in order to build positions of leadership within one or two key therapeutic areas (TAs). Our analysis for the R&D report found that companies with less volatility in their late-stage pipeline portfolios tend to achieve higher forecast peak sales per asset, implicating TA focus as strategy for maximum value creation.3

In a broader context, life sciences companies are expected to use M&A as a way to gain access to new markets and new technologies in order to expand their pipelines and sales channels. Deals and partnerships with established and upcoming local firms in emerging markets are likely to continue due to the clear advantage offered by having a local presence. Emerging markets can be very political with a high degree of protectionism towards locally produced products, meaning that deal-making with local producers is often necessary to gain a foothold in these growing markets. Furthermore, life sciences companies are anticipated to continue pursing deals of smaller innovative companies that aid larger life sciences companies increase operational efficiencies and reduce costs across their business functions. Additionally, deals at the convergence between the healthcare and technology sectors are also likely to see an uptick as life sciences companies respond to the need to expand their technical capabilities to enable the management and analysis of increasing amounts of data to drive more informed decision making.4

Ultimately, the environment in 2017 is likely to be more favourable for life sciences companies to pursue M&A activities. Increased deal-making will also be necessary for many companies to both adapt to the changing healthcare landscape and to achieve their strategic objectives.


1. Deloitte M&A Index 2017. See also:

2. Deloitte (2016). Measuring the return from pharmaceutical innovation 2016. See also: 

3. Ibid

4. Deloitte M&A Index 2017. See also:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions